Pharmaceutical Sanofi benefited, among other things, from an increase in sales of the asthma medicine Dupixent during the last quarter. Profits increased by over 3%. The French company is also developing potential COVID vaccine, of which doses have already been sold to the British government.
The sale of the product Dupixent increased by 70 percent. The relatively new medicine can be used for asthma and skin infections. There may also be new conditions for which the product can be approved.
Sanofi is developing potential COVID vaccine together with GlaxoSmithKline (GSK). On Wednesday it was announced that the British government had ordered 60 million doses from one of the means. The pharmacists expect the first possible vaccine to be approved in the first half of next year at the earliest. Sanofi and GSK are also talking about deliveries with, among others, the United States and the European Commission.
In the second quarter of 2020, the company’s turnover was 8.2 billion euros, a decrease of almost 5% on an annual basis. According to the French company, this is due, among other things, to the fact that a great deal has been hammered in the first quarter. Sanofi expects to meet the 2020 targets despite the coronacrisis.